Top

Published in:

01-04-2013 | Original article

Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG

Authors: Kory L. Alderson, Mitchell Luangrath, Megan M. Elsenheimer, Stephen D. Gillies, Fariba Navid, Alexander L. Rakhmilevich, Paul M. Sondel

Published in: Cancer Immunology, Immunotherapy | Issue 4/2013

Abstract

Targeted monoclonal antibodies (mAb) can be used therapeutically for tumors with identifiable antigens such as disialoganglioside GD2, expressed on neuroblastoma and melanoma tumors. Anti-GD2 mAbs (αGD2) can provide clinical benefit in patients with neuroblastoma. An important mechanism of mAb therapy is antibody-dependent cellular cytotoxicity (ADCC). Combinatorial therapeutic strategies can dramatically increase the anti-tumor response elicited by mAbs. We combined a novel αGD2 mAb, hu14.18K322A, with an immunostimulatory regimen of agonist CD40 mAb and class B CpG-ODN 1826 (CpG). Combination immunotherapy was more effective than the single therapeutic components in a syngeneic model of GD2-expressing B16 melanoma with minimal tumor burden. NK cell depletion in B6 mice showed that NK cells were required for the anti-tumor effect; however, anti-tumor responses were also observed in tumor-bearing SCID/beige mice. Thus, NK cell cytotoxicity did not appear to be essential. Peritoneal macrophages from anti-CD40 + CpG-treated mice inhibited tumor cells in vitro in an hu14.18K322A antibody-dependent manner. These data highlight the importance of myeloid cells as potential effectors in immunotherapy regimens utilizing tumor-specific mAb and suggest that further studies are needed to investigate the therapeutic potential of activated myeloid cells and their interaction with NK cells.

Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B, Hank JA, Sondel PM (2012) Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol 3:91. doi:10.3389/fphar.2012.00091 PubMedCrossRef

Alderson KL, Sondel PM (2011) Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011:379123. doi:10.1155/2011/379123 PubMedCrossRef

Yamane BH, Hank JA, Albertini MR, Sondel PM (2009) The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs 18(7):991–1000. doi:10.1517/13543780903048911 PubMedCrossRef

Sorkin LS, Otto M, Baldwin WM 3rd, Vail E, Gillies SD, Handgretinger R, Barfield RC, Ming YuH, Yu AL (2010) Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 149(1):135–142. doi:10.1016/j.pain.2010.01.024 PubMedCrossRef

Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278(5):3466–3473. doi:10.1074/jbc.M210665200 PubMedCrossRef

Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN (2005) Anti-neuroblastoma effect of ch 14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42(11):1311–1319. doi:10.1016/j.molimm.2004.12.018 PubMedCrossRef

Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL (2006) Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol 176(1):309–318PubMed

Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL (2007) Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology 120(3):412–423. doi:10.1111/j.1365-2567.2006.02517.x PubMedCrossRef

Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL (2005) CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol 174(10):6013–6022PubMed

10.

Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, Yu H (2001) Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol 166(1):89–94PubMed

11.

Straten PT, Guldberg P, Seremet T, Reisfeld RA, Zeuthen J, Becker JC (1998) Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci USA 95(15):8785–8790PubMedCrossRef

12.

Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174(1–2):83–93PubMedCrossRef

13.

Dyall R, Vasovic LV, Clynes RA, Nikolic-Zugic J (1999) Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur J Immunol 29(1):30–37. doi:10.1002/(SICI)1521-4141(199901)29:01<30:AID-IMMU30>3.0.CO;2-D PubMedCrossRef

14.

Hank JA, Albertini MR, Schiller J, Sondel PM (1993) Activation of multiple effector mechanisms to enhance tumor immunotherapy. J Immunother Emphasis Tumor Immunol 14(4):329–335PubMedCrossRef

15.

Ralph P, Nakoinz I (1984) Cooperation of IgG monoclonal antibodies in macrophage antibody-dependent cellular cytotoxicity (ADCC) to tumor targets. J Leukoc Biol 35(1):131–139PubMed

16.

Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199(12):1659–1669. doi:10.1084/jem.20040119 PubMedCrossRef

17.

Roder JC (1979) The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol 123(5):2168–2173PubMed

18.

Roder JC, Lohmann-Matthes ML, Domzig W, Wigzell H (1979) The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect. J Immunol 123(5):2174–2181PubMed

19.

Yokoyama WM, Kim S, French AR (2004) The dynamic life of natural killer cells. Annu Rev Immunol 22:405–429. doi:10.1146/annurev.immunol.22.012703.104711 PubMedCrossRef

20.

Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM (2010) Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 70(23):9554–9561. doi:10.1158/0008-5472.CAN-10-2211 PubMedCrossRef

21.

Joshi T, Ganesan LP, Cheney C, Ostrowski MC, Muthusamy N, Byrd JC, Tridandapani S (2009) The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma. PLoS ONE 4(1):e4208. doi:10.1371/journal.pone.0004208 PubMedCrossRef

22.

Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J (2009) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182(7):4415–4422. doi:10.4049/jimmunol.0713732 PubMedCrossRef

23.

Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M, Law CL, Grewal IS, Gerber HP (2009) Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer 100(1):113–117. doi:10.1038/sj.bjc.6604812 PubMedCrossRef

24.

Abes R, Gelize E, Fridman WH, Teillaud JL (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116(6):926–934. doi:10.1182/blood-2009-10-248609 PubMedCrossRef

25.

Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV (1998) Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 95(2):652–656PubMedCrossRef

26.

Fridman WH, Teillaud JL, Sautes-Fridman C, Pages F, Galon J, Zucman-Rossi J, Tartour E, Zitvogel L, Kroemer G (2011) The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol 2:66. doi:10.3389/fimmu.2011.00066 PubMed

27.

Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Gillies SD, Sondel PM (2001) The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 61(4):1500–1507PubMed

28.

Rakhmilevich AL, Baldeshwiler MJ, Van De Voort TJ, Felder MA, Yang RK, Kalogriopoulos NA, Koslov DS, Van Rooijen N, Sondel PM (2012) Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol Immunother. doi:10.1007/s00262-012-1236-2

29.

Liu W, Xiao X, Demirci G, Madsen J, Li XC (2012) Innate NK cells and macrophages recognize and reject allogeneic nonself in vivo via different mechanisms. J Immunol 188(6):2703–2711. doi:10.4049/jimmunol.1102997 PubMedCrossRef

30.

Saddawi-Konefka R OST, Vermi W, et al. (2012) Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Immunol Meet Abstr Suppl 188 (162.3)

31.

Roda JM, Parihar R, Carson WE 3rd (2005) CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175(3):1619–1627PubMed

32.

Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM, Biller E, Lehman A, Chaudhury AR, Jarjoura D, Burry RW, Carson WE 3rd (2011) IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-gamma production. J Immunol 186(6):3401–3409. doi:10.4049/jimmunol.1000328 PubMedCrossRef

33.

Xin L, Shelite TR, Gong B, Mendell NL, Soong L, Fang R, Walker DH (2012) Systemic treatment with CpG-B after sublethal rickettsial infection induces mouse death through indoleamine 2,3-dioxygenase (IDO). PLoS ONE 7(3):e34062. doi:10.1371/journal.pone.0034062PONE-D-11-21888 PubMedCrossRef

34.

Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ (1997) Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89(8):2994–2998PubMed

35.

Ballas ZK, Rasmussen WL, Krieg AM (1996) Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157(5):1840–1845PubMed

36.

van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ (2003) CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 63(17):5595–5600PubMed

37.

Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS (2009) Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 146(3):282–291. doi:10.1111/j.1365-2141.2009.07773.x PubMedCrossRef

38.

Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM (2009) Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother 32(6):622–631. doi:10.1097/CJI.0b013e3181ab23f1 PubMedCrossRef

39.

Tsai CY, Lu SL, Hu CW, Yeh CS, Lee GB, Lei HY (2012) Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J Immunol 188(1):68–76. doi:10.4049/jimmunol.1100344 PubMedCrossRef

40.

Buhtoiarov IN, Rakhmilevich AL, Lanier LL, Ranheim EA, Sondel PM (2009) Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules. J Immunol 182(4):1940–1953. doi:10.4049/jimmunol.0800443 PubMedCrossRef

41.

Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL (2006) In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol 79(6):1181–1192. doi:10.1189/jlb.0405191 PubMedCrossRef

42.

Rakhmilevich AL, Buhtoiarov IN, Malkovsky M, Sondel PM (2008) CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol Immunother 57(8):1151–1160. doi:10.1007/s00262-007-0447-4 PubMedCrossRef

43.

Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O’Dwyer PJ, Vonderheide RH (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024):1612–1616. doi:10.1126/science.1198443 PubMedCrossRef

44.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324–1334. doi:10.1056/NEJMoa0911123 PubMedCrossRef

45.

Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM (2010) Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study. J Clin Oncol 28(33):4969–4975. doi:10.1200/JCO.2009.27.8861 PubMedCrossRef

46.

Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F (2004) Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 22(17):3549–3557. doi:10.1200/JCO.2004.08.14322/17/3549 PubMedCrossRef

Title: Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG
Authors: Kory L. Alderson
Mitchell Luangrath
Megan M. Elsenheimer
Stephen D. Gillies
Fariba Navid
Alexander L. Rakhmilevich
Paul M. Sondel
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 4/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-012-1372-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis

Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy

Properties of monocytes generated from haematopoietic CD34+ stem cells from bone marrow of colon cancer patients

Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails

Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells

Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides

Keynote webinar | Spotlight on antibody–drug conjugates in cancer